tapebrief
SOLV · Q3 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

SOLV · Q4 2025 Earnings

Solventum

Reported February 26, 2026

30-second summary

Solventum closed FY2025 with Q4 organic growth of +3.5% and non-GAAP EPS of $1.57, capping a full year that beat the raised EPS guide ($6.11 actual vs $5.98–$6.08) and the organic growth guide (3.3% vs "high end of +2–3%"). The FY2026 guide is the real news: adjusted EPS of $6.40–$6.60 (+4.7–8.0% YoY), operating margin stepping up to 21.0–21.5% (+50–100bps), FCF recovering to ~$200M — but headline organic growth decelerating to +2.0–3.0% (3.0–4.0% ex ~100bps of SKU exits) and a doubling of tariff headwinds to $100–120M. Management is repositioning the story from "growth re-acceleration" to "margin expansion with growth optionality," and the SKU drag plus tariff doubling are the load-bearing reasons the top-line guide stepped down.

Headline numbers

EPS

Q4 FY2025

$1.57

Revenue

Q4 FY2025

$2.00B

-3.7% YoY

Gross margin

Q4 FY2025

51.4%

Free cash flow

Q4 FY2025

$0.03B

Operating margin

Q4 FY2025

6.2%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$2.00B-3.7%$2.10B-4.6%
EPS$1.57—$1.50+4.7%
Gross margin51.4%—55.8%-440bps
Operating margin6.2%—20.6%-1440bps
Free cash flow$0.03B—$-0.02B+250.0%

Guidance

FY2025 beat on adjusted EPS and organic sales growth despite severe FCF miss; FY2026 guidance shows EPS growth of 4.7–8.0%, margin expansion to 21.0–21.5%, but organic growth decelerating to 2.0–3.0%.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Adjusted EPSFY2025$5.98 to $6.08$6.11+$0.03 above high end of guideBeat
Organic Sales GrowthFY2025high end of +2.0% to +3.0% range3.3%+0.3 to +0.8pts above guidance rangeBeat
Free Cash FlowFY2025$150M to $250M-$10M-$160M to -$260M below rangeMissed

New guidance

MetricPeriodGuideYoY
Adjusted EPSFY2026$6.40 to $6.60+4.7% to +8.0% YoY
Organic Sales GrowthFY20262.0% to 3.0%—
Organic Sales Growth (excluding SKU exits)FY20263.0% to 4.0%—
Operating MarginFY202621.0% to 21.5%—
Free Cash FlowFY2026~$200M—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Operating Margin
FY2025
Implied ~20.0% to 20.5% (prior guidance referenced high end of organic growth; no explicit margin guide in prior quarter)20.5%In-line with historical performanceRaised

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
MedSurg$1.235B+5.2%
Dental Solutions$0.343B+8.6%
Health Information Systems$0.348B+3.7%
Advanced Wound Care$0.483B+3.8%
Infection Prevention and Surgical Solutions$0.752B+6.2%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Organic Sales Growth (Q4)3.5%
Adjusted Operating Margin (Q4)19.9%
MedSurg Operating Margin (Q4)15.5%
Dental Solutions Operating Margin (Q4)24.4%
Health Information Systems Operating Margin (Q4)38.3%
Full-Year Adjusted Operating Margin20.5%
Full-Year Organic Sales Growth3.3%
2026 Guidance: Organic Sales Growth2.0% to 3.0%

Management tone

Q1 FY2025 separation-survival → Q2 FY2025 ownership-and-raise → Q3 FY2025 execution-with-divestiture-noise → Q4 FY2025 LRP-acceleration-with-margin-pivot.

Three quarters ago the central question, per the CEO's own framing, was "whether we could ever get to the LRP targets." This quarter his answer: "It's pretty clear we will not only get there, but we might do it faster than expected. Hopefully we do it this year." The shift from defending the 4–5% organic / 23–25% margin LRP as a multi-year ambition to suggesting it might land this year is the most aggressive forward-looking statement management has made since the spin. It is also notable because the FY2026 reported organic guide of +2.0–3.0% does not by itself support that timeline — the LRP acceleration is being framed primarily through margin and ex-SKU growth, not headline organic.

The AI-as-threat-to-HIS question, which had hung over the autonomous coding story since the Ensemble partnership disclosure in Q2, got its most direct rebuttal yet: "we see artificial intelligence as an opportunity more than we do a threat...we see it as a tool to solve for autonomous coding, not a competitor." Management cited "close to a million plus" proprietary reimbursement rules and algorithms as the moat. This is a meaningful reframing — Q2 and Q3 calls treated AI in HIS as a distribution and product opportunity (Ensemble); this call treats it as a competitive-moat conversation that management is willing to litigate head-on. HIS organic decelerating to +3.7% this quarter makes the rebuttal more important, not less.

M&A messaging escalated again. Q2 FY2025 called M&A "an enhancement, not a requirement." This quarter management framed tuck-ins as "a perpetual lever that we're going to continue to flex...acquiring companies on a tuck-in basis in a serial fashion," citing Acera as proof of concept. The progression from "optional" to "perpetual and serial" is a real shift in capital-allocation posture, and consistent with PNF proceeds being available for deployment.

Where management hedged: tariffs are doubling in FY2026 to $100–120M, and the language around the Supreme Court ruling and "evolving regulatory environment" is the most cautious posture of the year. The Q2 narrative — tariffs as a tailwind to the raise — has fully inverted. And the language around the 3M raw material supply agreement step-up ("~100 basis points potential in 2027 if contractual option is exercised") introduces a new, previously-unflagged FY2027 risk that did not feature in prior calls.

Recurring themes management leaned on this quarter:

Accelerated path to long-range plan targets (4-5% revenue growth, 23-25% operating margins)Commercial enhancements driving volume growth through specialized sales teams and new product launchesSeparation from 3M creating future margin expansion opportunities through IT systems ownership and Transform for the Future programPortfolio optimization as ongoing value creation lever via serial tuck-in acquisitions (Acera as proof point)AI as opportunity, not threat, for autonomous coding competitive differentiation in HIS segmentManaging persistent tariff and supply chain headwinds while expanding margins

Risks management surfaced:

Tariff impacts estimated at 100-120 million in 2026 with evolving regulatory environment post-Supreme Court rulingCompetitive entry into autonomous coding space and HIS business from companies leveraging AIERP implementation risks and execution complexity across multiple waves through 20263M raw material supply agreement step-up cost of ~100 basis points potential in 2027 if contractual option is exercisedFirst quarter 2026 headwinds from 180 basis points tough comparison and seasonal gross margin pressure

Answers to last quarter's watch list

Q4 FY2025 MedSurg / IPSS recovery. IPSS organic rebounded to +6.2% from Q3's 0.0%, and MedSurg organic to +5.2% from +1.1%. The single most important segment data point cleared the +4% bar decisively, restoring the sterilization-assurance/NPWT/IV-site launch thesis after one quarter of doubt.
Resolved positively
Dental sustainability above +5% organic. Dental organic accelerated to +8.6% from +6.5%, the strongest segment growth on the page and well above the +5% bar. The new-product / market-share narrative is now two quarters into validation.
Resolved positively
Initial FY2026 FCF framing. Management guided FY2026 FCF to ~$200M, a recovery from FY2025 actual of -$10M but well below the original FY2025 $450–550M framing that anchored the spin. The normalization path exists but at a lower altitude than the spin-era narrative implied — and credibility on cash is now load-bearing after two consecutive misses.
Resolved negatively
"Transform for the Future" execution detail. Margin guidance of 21.0–21.5% (+50–100bps) absorbing $40–60M of incremental tariff headwind is the implicit Transform contribution, but management did not disclose cost cadence, savings phasing, or COGS/SG&A split in the press release. The directional signal is there; the granular phasing is not.
Continue monitoring
PNF divestiture proceeds deployment and M&A timing. Management formalized serial tuck-in M&A as a "perpetual lever," citing Acera as the proof point. The cadence and deleveraging glide path were not specifically quantified in the press release.
Resolved positively
FY2026 organic growth guide vs. 100 bps SKU drag. FY2026 reported organic guide is +2.0–3.0% with ~100bps SKU exit drag, implying ex-SKU growth of +3.0–4.0%. The low end of the ex-SKU range (+3.0%) just barely clears the "above 3%" bar; the high end (+4.0%) is below FY2025's +3.3% reported actual when adjusted for the smaller FY2025 SKU drag. The "underlying acceleration" thesis is intact but only marginally.
Continue monitoring

What to watch into next quarter

Whether the +3.0–4.0% ex-SKU FY2026 organic range proves conservative. A Q1 FY2026 reported organic print above +2.5% (despite the 180bps tough comparison management flagged) would suggest management is sandbagging; below +2.0% would suggest the deceleration is real.

Q1 FY2026 FCF. Management guided to ~$200M FY but flagged "normal sequential seasonal headwind" in Q1. After two consecutive cash misses, the first Q1 print is the credibility check on the recovery path.

Tariff impact phasing within FY2026. The $100–120M is annualized; the Q1 P&L disclosure of the realized headwind and its margin offset is the cleanest read on whether Transform for the Future savings can absorb it.

HIS organic trajectory. The +3.7% Q4 deceleration from +5.6% in Q3 needs a recovery above +5% in Q1 FY2026 to keep the "AI-as-opportunity" narrative anchored in segment performance, not just rhetoric.

Cadence and target sizing of tuck-in M&A. Management committed to "serial" tuck-ins; the absence of stated deal cadence, average target size, and ROIC bar leaves a gap. Watch for a second announced transaction in 1H FY2026 to validate "serial."

3M raw material supply agreement step-up disclosure. The ~100bps FY2027 risk if the contractual option is exercised was newly disclosed this quarter. Watch for any FY2026 commentary on negotiation status or the decision timeline — this is now a discrete watch item, not hypothetical noise.

Sources

  1. Solventum Q4 FY2025 Form 8-K Exhibit 99.1 (press release) — https://www.sec.gov/Archives/edgar/data/1964738/000196473826000005/q42025-8kerexx991.htm
  2. Solventum Q4 FY2025 earnings call — management prepared remarks (transcript-sourced commentary on operating margin guidance and LRP timing)
  3. Solventum Q3 FY2025 Tapebrief (prior-quarter watch list and guidance baseline)
  4. Solventum Q2 FY2025 Tapebrief (tone and growth-driver context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.